Long Junshan,Zhang Jing,Su Xiaoxia,et al.Research advances of targeted therapy for neuroblastoma in children[J].Journal of Clinical Pediatric Surgery,2023,22(07):619-624.[doi:10.3760/cma.j.cn101785-202303039-004]
儿童神经母细胞瘤靶向治疗的研究进展
- Title:
- Research advances of targeted therapy for neuroblastoma in children
- Keywords:
- Neuroblastoma; Molecular Targeted Therapy; Surgical Procedures; Operative; Child
- 摘要:
- 神经母细胞瘤（neuroblastoma，NB）是一种儿童恶性实体肿瘤，通常起源于交感神经节细胞。传统上可通过化疗、手术和放疗等手段控制NB的进展，但往往并不能达到完全治愈的目的。靶向治疗作为一种新型的治疗方法，为NB的治疗提供了新的思路。靶向治疗是利用药物或者其他方式特异性作用于肿瘤细胞的某些分子，从而抑制肿瘤细胞的生长和转移。本文对目前NB的靶向治疗研究进展（如针对NB特异性表达的抗体、针对NB相关信号通路的靶向药物以及其他类型的靶向治疗等内容）进行综述，为NB的治疗提供新的策略。
- Abstract:
- Neuroblastoma (NB) is a malignant solid tumor typically originating from sympathetic nervous system cells in children.Although traditional interventions of chemotherapy, surgery and radiotherapy may arrest the progression of NB, they often fail to obtain a complete cure.Recently targeted therapy has emerged as a novel therapeutic option for NB.Drugs or other means are employed for selectively acting upon certain molecules in tumor cells, thus inhibiting their growth and metastasis.This review summarized the latest researches of targeted therapy for NB, such as antibodies targeting NB-specific expression and targeted drugs for NB-related signaling pathways.
参考文献/References:
[1] Matthay KK, Maris JM, Schleiermacher G, et al.Neuroblastoma[J].Nat Rev Dis Primers, 2016, 2:16078.DOI:10.1038/nrdp.2016.78.
[2] Park JR, Bagatell R, Cohn SL, et al.Revisions to the International Neuroblastoma Response Criteria:a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting[J].J Clin Oncol, 2017, 35(22):2580-2587.DOI:10.1200/JCO.2016.72.0177.
[3] Brodeur GM.Neuroblastoma:biological insights into a clinical enigma[J].Nat Rev Cancer, 2003, 3(3):203-216.DOI:10.1038/nrc1014.
[4] Mossé YP.Anaplastic lymphoma kinase as a cancer target in pediatric malignancies[J].Clin Cancer Res, 2016, 22(3):546-552.DOI:10.1158/1078-0432.CCR-14-1100.
[5] Cheung NKV, Dyer MA.Neuroblastoma:developmental biology, cancer genomics and immunotherapy[J].Nat Rev Cancer, 2013, 13(6):397-411.DOI:10.1038/nrc3526.
[6] Yu AL, Gilman AL, Ozkaynak MF, et al.Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma[J].N Engl J Med, 2010, 363(14):1324-1334.DOI:10.1056/NEJMoa0911123.
[7] Pugh TJ, Morozova O, Attiyeh EF, et al.The genetic landscape of high-risk neuroblastoma[J].Nat Genet, 2013, 45(3):279-284.DOI:10.1038/ng.2529.
[8] Suzuki M, Cheung NKV.Disialoganglioside GD2 as a therapeutic target for human diseases[J].Expert Opin Ther Targets, 2015, 19(3):349-362.DOI:10.1517/14728222.2014.986459.
[9] Yu AL, Gilman AL, Ozkaynak MF, et al.Long-term follow-up of a phase III study of ch14.18(dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma:COG study ANBL0032[J].Clin Cancer Res, 2021, 27(8):2179-2189.DOI:10.1158/1078-0432.CCR-20-3909.
[10] Mody R, Naranjo A, Van Ryn C, et al.Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221):an open-label, randomised, phase 2 trial[J].Lancet Oncol, 2017, 18(7):946-957.DOI:10.1016/S1470-2045(17)30355-8.
[11] Shusterman S, London WB, Gillies SD, et al.Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma:a Children’s Oncology Group (COG) phase II study[J].J Clin Oncol, 2010, 28(33):4969-4975.DOI:10.1200/JCO.2009.27.8861.
[12] González A, González-González A, Alonso-González C, et al.Melatonin inhibits angiogenesis in SH-SY5Y human neuroblastoma cells by downregulation of VEGF[J].Oncol Rep, 2017, 37(4):2433-2440.DOI:10.3892/or.2017.5446.
[13] Modak S, Kushner BH, Basu E, et al.Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma:results of a phase II study[J].Pediatr Blood Cancer, 2017, 64(8):e26448.DOI:10.1002/pbc.26448.
[14] Calafiore L, Amoroso L, Della Casa Alberighi O, et al.Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma[J].Ann Oncol, 2013, 24(5):1406-1413.DOI:10.1093/annonc/mds648.
[15] Henssen A, Althoff K, Odersky A, et al.Targeting MYCN-driven transcription by BET-bromodomain inhibition[J].Clin Cancer Res, 2016, 22(10):2470-2481.DOI:10.1158/1078-0432.CCR-15-1449.
[16] Delmore JE, Issa GC, Lemieux ME, et al.BET bromodomain inhibition as a therapeutic strategy to target c-Myc[J].Cell, 2011, 146(6):904-917.DOI:10.1016/j.cell.2011.08.017.
[17] Sauvage D, Bosseler M, Viry E, et al.The BET protein inhibitor JQ1 decreases hypoxia and improves the therapeutic benefit of anti-PD-1 in a high-risk neuroblastoma mouse model[J].Cells, 2022, 11(18):2783.DOI:10.3390/cells11182783.
[18] DuBois SG, Marachelian A, Fox E, et al.Phase I study of the Aurora a kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma:a NANT (new approaches to neuroblastoma therapy) trial[J].J Clin Oncol, 2016, 34(12):1368-1375.DOI:10.1200/JCO.2015.65.4889.
[19] Seto E, Yoshida M.Erasers of histone acetylation:the histone deacetylase enzymes[J].Cold Spring Harb Perspect Biol, 2014, 6(4):a018713.DOI:10.1101/cshperspect.a018713.
[20] Cheung BB, Kleynhans A, Mittra R, et al.A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma[J].Oncogene, 2021, 40(13):2367-2381.DOI:10.1038/s41388-021-01712-w.
[21] Waldeck K, Cullinane C, Ardley K, et al.Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model[J].Int J Cancer, 2016, 139(1):194-204.DOI:10.1002/ijc.30056.
[22] Chava S, Reynolds CP, Pathania AS, et al.miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma[J].Mol Oncol, 2020, 14(1):180-196.DOI:10.1002/1878-0261.12588.
[23] Trigg RM, Turner SD.ALK in neuroblastoma:biological and therapeutic implications[J].Cancers (Basel), 2018, 10(4):113.DOI:10.3390/cancers10040113.
[24] Hallberg B, Palmer RH.The role of the ALK receptor in cancer biology[J].Ann Oncol, 2016, 27(Suppl 3):iii4-iii15.DOI:10.1093/annonc/mdw301.
[25] Schulte JH, Schulte S, Heukamp LC, et al.Targeted therapy for neuroblastoma:ALK inhibitors[J].Klin Padiatr, 2013, 225(6):303-308.DOI:10.1055/s-0033-1357132.
[26] Foster JH, Voss SD, Hall DC, et al.Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma:a children’s oncology group study (ADVL0912)[J].Clin Cancer Res, 2021, 27(13):3543-3548.DOI:10.1158/1078-0432.CCR-20-4224.
[27] Cervantes-Madrid D, Szydzik J, Lind DE, et al.Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells[J].Sci Rep, 2019, 9(1):19353.DOI:10.1038/s41598-019-55060-7.
[28] Fischer M, Moreno L, Ziegler DS, et al.Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies:an open-label, multicentre, phase 1, dose-escalation and dose-expansion study[J].Lancet Oncol, 2021, 22(12):1764-1776.DOI:10.1016/S1470-2045(21)00536-2.
[29] Redaelli S, Ceccon M, Zappa M, et al.Lorlatinib treatment elicits multiple on-and off-target mechanisms of resistance in ALK-driven cancer[J].Cancer Res, 2018, 78(24):6866-6880.DOI:10.1158/0008-5472.CAN-18-1867.
[30] O’Donohue TJ, Ibá?ez G, Coutinho DF, et al.Translational strategies for repotrectinib in neuroblastoma[J].Mol Cancer Ther, 2021, 20(11):2189-2197.DOI:10.1158/1535-7163.MCT-21-0126.
[31] Morgenstern DA, Marzouki M, Bartels U, et al.Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors[J].Pediatr Blood Cancer, 2014, 61(1):128-133.DOI:10.1002/pbc.24656.
[32] Fulda S.The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma[J].Curr Cancer Drug Targets, 2009, 9(6):729-737.DOI:10.2174/156800909789271521.
[33] Chilamakuri R, Agarwal S.Dual targeting of PI3K and HDAC by CUDC-907 inhibits pediatric neuroblastoma growth[J].Cancers (Basel), 2022, 14(4):1067.DOI:10.3390/cancers14041067.
[34] Mlakar V, Morel E, Mlakar SJ, et al.A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma[J].J Exp Clin Cancer Res, 2021, 40(1):189.DOI:10.1186/s13046-021-01967-x.
[35] Yu XY, Fan HJ, Jiang XR, et al.Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma[J].Oncol Lett, 2020, 20(4):52.DOI:10.3892/ol.2020.11913.
[36] Wang HW, Wang XR, Xu LP, et al.TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma[J].BMC Genom Data, 2022, 23(1):41.DOI:10.1186/s12863-022-01059-5.
[37] Bhoopathi P, Gorantla B, Sailaja GS, et al.Retraction:SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT[J].PLoS One, 2020, 15(1):e0228246.DOI:10.1371/journal.pone.0228246.
[38] Lamers F, Schild L, den Hartog IJM, et al.Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth[J].Eur J Cancer, 2012, 48(16):3093-3103.DOI:10.1016/j.ejca.2012.01.037.
[39] Tsai HC, Li HL, Van Neste L, et al.Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells[J].Cancer Cell, 2012, 21(3):430-446.DOI:10.1016/j.ccr.2011.12.029.
[40] Lin HY, Chuang JH, Wang PW, et al.5-aza-2’-deoxycytidine induces a RIG-I-related innate immune response by modulating mitochondria stress in neuroblastoma[J].Cells, 2020, 9(9):1920.DOI:10.3390/cells9091920.
[41] Li ZP, Chen HJ.miR-34a inhibits proliferation, migration and invasion of paediatric neuroblastoma cells via targeting HNF4α[J].Artif Cells Nanomed Biotechnol, 2019, 47(1):3072-3078.DOI:10.1080/21691401.2019.1637886.
[42] Baranowska-Kortylewicz J, Kortylewicz ZP, McIntyre EM, et al.Multifarious functions of butyrylcholinesterase in neuroblastoma:impact of BCHE deletion on the neuroblastoma growth in vitro and in vivo[J].J Pediatr Hematol Oncol, 2022, 44(6):293-304.DOI:10.1097/MPH.0000000000002285.
[43] Louis CU, Savoldo B, Dotti G, et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood, 2011, 118(23):6050-6056.DOI:10.1182/blood-2011-05-354449.
[44] Kendsersky NM, Lindsay J, Kolb EA, et al.The B7-H3-targeting antibody-drug conjugate m276-SL-PBD is potently effective against pediatric cancer preclinical solid tumor models[J].Clin Cancer Res, 2021, 27(10):2938-2946.DOI:10.1158/1078-0432.CCR-20-4221.
[45] Chatterjee N, Bivona TG.Polytherapy and targeted cancer drug resistance[J].Trends Cancer, 2019, 5(3):170-182.DOI:10.1016/j.trecan.2019.02.003.
相似文献/References:
[1]郭春宝,王珊,金先庆,等.Cochrane系统评价方法对神经母细胞瘤分子与生物标记物的Meta分析[J].临床小儿外科杂志,2008,7(01):2.
[2]未德成,王忠荣,张燕敏,等.脂氧合酶抑制剂NDGA对人神经母细胞瘤SK-N-SH细胞生物学特性的影响[J].临床小儿外科杂志,2008,7(01):3.
[3]陈新让,王家祥,余捷凯,等.基于支持向量机神经母细胞瘤血清蛋白质标记物的检测及临床应用[J].临床小儿外科杂志,2008,7(02):12.
[4]罗远建,金科,甘青,等.儿童神经母细胞瘤的影像学表现[J].临床小儿外科杂志,2007,6(02):22.
[5]李昆昆 金先庆 牟廷刚 陈建飞 赵利华 丁雄辉 孙艳辉 王士奇. ATRA耐药基因HA117相关蛋白在四种恶性肿瘤的表达及临床意义[J].临床小儿外科杂志,2011,10(04):250.
[J].Journal of Clinical Pediatric Surgery,2011,10(07):250.
[6]沙永亮 吴晔明. 化疗及非化疗组神经母细胞瘤干细胞标志物的表达及意义[J].临床小儿外科杂志,2011,10(04):254.
[J].Journal of Clinical Pediatric Surgery,2011,10(07):254.
[7]刘涛 韩英 祝秀丹 王焕民 秦红 邹焱. Wnt—5a基因在神经母细胞瘤中的表达及意义[J].临床小儿外科杂志,2011,10(05):333.
[J].Journal of Clinical Pediatric Surgery,2011,10(07):333.
[8]顾 涛 鹿洪亭 董 蒨.Kai1/CD82表达水平与神经母细胞瘤转移的关系探讨[J].临床小儿外科杂志,2013,12(02):100.[doi:10.3969/j.issn.1671— 6353.2013.02.007]
GU Tao,LU Hong-ting,DONG Qian.The relationship between Kai1/CD82 expression and metastasis of neuroblastoma[J].Journal of Clinical Pediatric Surgery,2013,12(07):100.[doi:10.3969/j.issn.1671— 6353.2013.02.007]
[9]邢莉莉,吴晔明,张弛.熊果酸对神经母细胞瘤细胞增殖凋亡及 MYCN表达的影响[J].临床小儿外科杂志,2013,12(03):196.[doi:10.3969/j.issn.1671—6353.2013.03.010]
XING Li li,WU Ye ming,ZHANG Chi..Ursolic acid effects proliferation、apoptosis and MYCN expression of neuroblastoma cell[J].Journal of Clinical Pediatric Surgery,2013,12(07):196.[doi:10.3969/j.issn.1671—6353.2013.03.010]
[10]张雁冰 刘朝阳 卢其 周小渔. RNA干扰对神经母细胞瘤细胞VEGFA的ｍRNA表达的影响[J].临床小儿外科杂志,2013,12(06):471.
[11]张鑫,金倩涯,袁晓军.青少年和成人神经母细胞瘤诊疗策略和挑战:病例报告并文献复习[J].临床小儿外科杂志,2023,22(07):625.[doi:10.3760/cma.j.cn101785-202306028-005]
Zhang Xin,Jin Qianya,Yuan Xiaojun.Challenges and strategies in the diagnosis and treatment of neuroblastoma in adolescents and adults: one case report with a literature review[J].Journal of Clinical Pediatric Surgery,2023,22(07):625.[doi:10.3760/cma.j.cn101785-202306028-005]
备注/Memo
收稿日期:2023-03-13。
基金项目:海南省临床医学中心建设项目（QWYH202175）
通讯作者:董琦,Email:dqearth@163.com